Literature DB >> 9634476

Mice carrying a CD20 gene disruption.

T L O'Keefe1, G T Williams, S L Davies, M S Neuberger.   

Abstract

CD20 is a hallmark antigen of B lymphocytes. Its expression is restricted to precursor and mature B cells but it is not expressed on plasma cells. The protein is a membrane-embedded phosphoprotein that appears likely to transverse the membrane four times. Its function is unknown although CD20 has been variously proposed to play a role in B-cell activation, proliferation, and calcium transport. A unique homologue of human CD20 has been described in mouse, which also shows a B-cell-specific pattern of expression. Here we describe the generating of mice carrying a CD20 gene disruption. So far, we have failed to detect any major effect of the gene disruption on the differentiation and function of B lymphocytes as judged by the expression of surface markers, antigen receptor signaling, proliferative responses, or calcium uptake. We did note, however, that the mice homozygous for the gene disruption [generated by intercrossing (129 x C57BL/6)F1 CD20+/- heterozygotes] showed a substantial depletion of the sub-population of peritoneal B cells that lack expression of the B220 (RA3-6B2) isoform of CD45. The loss of the IgM+ 6B2- peritoneal B cells is not, however, attributable to the CD20 gene disruption itself. Rather, it segregates with a polymorphic difference between the 129 and C57BL/6 strains that is linked to the CD20 locus which, intriguingly, is itself close to the CD5 gene. This demonstrates that caution must be exercised when comparing the phenotypes of F2 litter-mates generated from crosses between 129 embryonic stem-cell-derived chimeras and mice of other strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634476     DOI: 10.1007/s002510050412

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  20 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 2.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

Review 3.  Update on rituximab.

Authors:  R Eisenberg
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 4.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 5.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

Review 6.  Rituximab resistance.

Authors:  Andrew R Rezvani; David G Maloney
Journal:  Best Pract Res Clin Haematol       Date:  2011-04-13       Impact factor: 3.020

7.  Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation.

Authors:  M R Ehrenstein; M S Neuberger
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

8.  Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice.

Authors:  Jerold E Rehg; John P Sundberg
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

Review 9.  Mechanisms of autoimmunity.

Authors:  Robert Eisenberg
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 10.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.